story of the week
Regorafenib for Patients With Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Regorafenib for Patients With Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet 2016 Dec 05;[EPub Ahead of Print], J Bruix, S Qin, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, O Yokosuka, O Rosmorduc, V Breder, R Gerolami, G Masi, PJ Ross, T Song, JP Bronowicki, I Ollivier-Hourmand, M Kudo, AL Cheng, JM Llovet, RS Finn, MA LeBerre, A Baumhauer, G Meinhardt, G HanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.